Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study

Abstract

Filgotinib is a selective JAK1 (Janus kinase) inhibitor, filed in Japan for the treatment of rheumatoid arthritis. In this paper, we present the data of development and validation of a high-performance liquid chromatography (HPLC) method for the quantitation of filgotinib in mice plasma as per the FDA regulatory guideline. The method involves the extraction of filgotinib along with internal standard (IS, tofacitinib) from mice plasma (100 µL) using ethyl acetate as an extraction solvent. The chromatographic analysis was performed using an isocratic mobile phase comprising 10 mM ammonium acetate (pH 4.5) and acetonitrile (70:30, v/v) at a flow-rate of 0.8 mL/min on a Hypersil Gold C₁₈ column. The UV detection wavelength was set at λ_max 300 nm. Filgotinib and the IS eluted at 5.56 and 4.28 min, respectively with a total run time of 10 min. The calibration curve was linear over a concentration range of 0.05 to 5.00 μg/mL (r ²⁺=≥0.992). The intra- and inter-day precision and accuracy results were within the acceptable limits. Results of stability studies indicated that filgotinib was stable on bench-top, in auto-sampler, up to three freeze/thaw cycles and long-term storage at −80°C. The validated HPLC method was successfully applied to a pharmacokinetic study in mice.

Key words

Filgotinib - HPLC - method validation - mice plasma - pharmacokinetics

• References

• 1 Buer JK. A history of the term DMARD. Inflammopharmacology 2015; 23: 163-171
• 2 Doan T, Massarotti E. Rheumatoid Arthritis: An overview of new and emerging therapies. J Clin Pharmacol 2005; 45: 751-762
• 3 Detert J, Klaus P. Biologic monotherapy in the treatment of rheumatoid arthritis. Biologics 2015; 9: 35-43
• 4 Mócsai A, Kovács L, Gergely P. What is the future of targeted therapy in rheumatology: Biologics or small molecules?. BMC Med 2014; 12: 43
• 5 O’Shea JJ, Kontzias A, Yamaoko K. et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013; 72: 111-115
• 6 Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017; 13: 234-243
• 7 Chough C, Lee S, Joung M. et al. Design, Synthesis and Evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. Med Chem Comm 2018; 9: 477
• 8 O’Shea JJ, Gadina M. Selective janus kinase inhibitors come of age. Nat Rev Rheumatol 2019; 15: 74-75
• 9 Van Rompaey L, Galien R, van der Aar EM. et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013; 191: 3568-3577
• 10 Genovese M, Westhovens R, Meuleners L. et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: Patient-reported outcomes. Arthritis Res Ther 2018; 20: 57
• 11 Pharma Japan (2019) https://pj.jiho.jp/article/240785
• 12 Namour F, Diderichsen PM, Cox E. et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of Phase IIB dose selection. Clin Pharmacokinet 2015; 54: 859-874
• 13 Srinivas NR. Comment on: Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of Phase IIB dose selection. Clin Pharmacokinet 2015; 54: 1293-1295
• 14 Dixit A, Kiran V, Gabani BB. et al. Validated LC-MS/MS method for quantitation of a selective JAK1 inhibitor, filgotinib in rat plasma and its application to a pharmacokinetics study in rats. Biomed Chromatogr. 2020 (accepted)
• 15 US DHHS, FDA, CDER, CVM, Guidance for Industry: Bioanalytical Method Validation, U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CV). 2018. Rockville, MD, USA:
• 16 Srinivas NR. Should commonly prescribed drugs be avoided as internal standard choices in new assays for clinical samples?. Bioanalysis. 2016; 8: 607-610